Yu Imamura

Yu Imamura

Auto-generated profile, based on publicly available information

Yu Imamura

Affiliation Department of Gastroenterological Surgery, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 October 2020 in Annals of Gastroenterological Surgery
Verified
Journal Article
Open access
PDF file
YIYu Imamura
Yu Imamura
MWMasayuki Watanabe
Masayuki Watanabe
EOEIJI OKI
EIJI OKI
MMMasaru Morita
Masaru Morita
HBHideo Baba
Hideo Baba
The incidence of esophagogastric junction (EGJ) adenocarcinoma has been gradually increasing in Asia, just like in Western countries a few decades ago. Despite recent advances in next‐generation sequencing and multimodal treatments, EGJ adenocarcinoma is still an aggressive malignancy with poor outcomes. Clinically, EGJ adenocarcinoma can be separated into Barrett's adenocarcinoma and cardiac adenocarcinoma, with frequent similarities observed. Barrett's adenocarcinoma is likely to be of gastric origin in terms of its premalignant background, risk factors, and stem cell regulators. Recent comprehensive genomic analyses suggest that immunotherapy may be essential for high‐level microsatellite instability (MSI‐H)‐ and Epstein‐Barr virus (EBV)‐associated subtypes, and against the immunosuppressive phenotype in genomically stable (GS) subtypes, in the treatment of EGJ and gastric adenocarcinoma. Although the chromosomal instability (CIN) subtype dominates EGJ adenocarcinoma, there is still a need to investigate the other molecular subtypes and their targets. Because of the distinctive characteristics of tumor location of EGJ adenocarcinoma, we also described the results of a multicenter cohort study of EGJ adenocarcinoma, comparing Siewert type I (distal esophagus), II (cardia of the stomach), and III (subcardia) tumors. We show that type I tumors were frequently accompanied by Barrett's esophagus (78%, P < .0001), with a significantly unfavorable outcome (multivariate EGJ‐cancer‐specific mortality hazard ratio = 1.81, 95% CI, 1.06‐2.97; P = .031). In addition, over half (56%) of these cases experienced disease recurrence in the lymph nodes. Our findings suggest that Barrett's adenocarcinoma may be an aggressive phenotype of EGJ adenocarcinoma due to the potential risk of tumor spread through the complex lympho‐vascular network of the esophagus.

14 December 2018 in Digestion
Verified
Journal Article
Open access
PDF file
YIYu Imamura
Yu Imamura
MWMasayuki Watanabe
Masayuki Watanabe
TTTasuku Toihata
Tasuku Toihata
MTManabu Takamatsu
Manabu Takamatsu
HKHiroshi Kawachi
Hiroshi Kawachi
TSTakeshi Sano
Takeshi Sano
Background: The incidence trend of esophagogastric junction (EGJ) adenocarcinoma in Japan has not been sufficiently investigated. Little is known about the microsatellite instability (MSI) status of this tumor. Summary: Previously published studies analyzing the trend of EGJ adenocarcinoma in Japan were reviewed. And a trend of surgically resected cases (Siewert type I-III) utilizing a retrospective multicenter cohort of 379 patients from 4 academic institutions in Japan investigated. Although an increasing trend in the last 2 reports was considered controversial, our cohort demonstrated a growing number of EGJ adenocarcinoma cases between 2006 and 2013. This trend was evident, especially in Siewert type I cases. In the previous 16 studies that performed MSI testing, MSI-high tumors ranged 0–8.3%, though there were no fixed microsatellite markers on EGJ adenocarcinoma. In a recent comprehensive genetic analysis by The Cancer Genome Atlas, MSI testing using the following 7 markers, BAT25, BAT26, BAT40, D2S123, D5S346, D17S250 and TGFR-II showed a favorable correlation with hypermutated tumors. We performed MSI testing using 6 of those markers, except TGFR-II, on 206 cases from one institution, and detected 15 cases (7.3%) with MSI-high. The prevalence of MSI-high was 0% in Siewert type I, 7.6% in type II, and 16.7% in type III. Key message: The number of surgically resected EGJ adenocarcinoma cases gradually increased, and MSI-high was infrequent in Siewert type I-II tumors in our Japanese cohort. Considering MSI-high as a predictive biomarker for emerging immune checkpoint inhibitors, MSI status is becoming more beneficial in EGJ adenocarcinoma.

27 February 2016 in Oncotarget
Verified
Journal Article
Open access
RTRyuma Tokunaga
Ryuma Tokunaga
YIYu Imamura
Yu Imamura
KNKenichi Nakamura
Kenichi Nakamura
TITakatsugu Ishimoto
Takatsugu Ishimoto
SNShigeki Nakagawa
Shigeki Nakagawa
HBHideo Baba
Hideo Baba
Fibroblast growth factor receptor 2 expression, but not its genetic amplification, is associated with tumor growth and worse survival in esophagogastric junction adenocarcinoma Fibroblast growth factor receptor 2 expression, but not its genetic amplification, is associated with tumor growth and worse survival in esophagogastric junction adenocarcinoma

14 April 2022 in Langenbeck's Archives of Surgery
Verified
Journal Article
Closed access
PDF file
SMSuguru Maruyama
Suguru Maruyama
AOAkihiko Okamura
Akihiko Okamura
YKYasukazu Kanie
Yasukazu Kanie
KSKei Sakamoto
Kei Sakamoto
DFDaisuke Fujiwara
Daisuke Fujiwara
MWMasayuki Watanabe
Masayuki Watanabe

8 November 2023 in Journal of Gastrointestinal Surgery
Verified
Journal Article
Closed access
PDF file
SHSoshi Hori
Soshi Hori
YIYu Imamura
Yu Imamura
YKYasukazu Kanie
Yasukazu Kanie
AOAkihiko Okamura
Akihiko Okamura
JKJun Kanamori
Jun Kanamori
MWMasayuki Watanabe
Masayuki Watanabe

30 September 2020 in International Journal of Cancer
Verified
Journal Article
Closed access
PDF file
YIYu Imamura
Yu Imamura
TTTasuku Toihata
Tasuku Toihata
IHIkumi Haraguchi
Ikumi Haraguchi
YOYoko Ogata
Yoko Ogata
MTManabu Takamatsu
Manabu Takamatsu
MWMasayuki Watanabe
Masayuki Watanabe